Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.

Lindsay A Courtney; Jennifer N Clements; Diana Isaacs; Jamie M Pitlick; Sara Mandy Reece; Heather P Whitley

doi:10.1016/j.dsx.2025.103314

Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.

Lindsay A Courtney
, Jennifer N Clements
, Diana Isaacs
, Jamie M Pitlick
, Sara Mandy Reece
, Heather P Whitley

Philadelphia College of Osteopathic Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

AIMS: This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages.

METHODS: The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of Clinical Pharmacy members, convened an independent committee to evaluate the role of compounded incretin mimetics.

RESULTS: There is limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide. However, there remain significant legal and safety concerns since compounded incretins do not undergo approval by the Food and Drug Administration.

CONCLUSION: Whenever possible, healthcare providers should make every effort to assist patients with obtaining approved medications. If patients choose to obtain compounded incretins, providers can encourage safety by ensuring use of reputable compounding pharmacies and routinely monitoring patients for safety and efficacy of the compounded product.

Original language	American English
Journal	Diabetes and Metabolic Syndrome
Volume	19
Issue number	9
DOIs	https://doi.org/10.1016/j.dsx.2025.103314
State	Published - Sep 1 2025

Access to Document

10.1016/j.dsx.2025.103314License: Unspecified

http://digitalcommons.pcom.edu/scholarly_papers/2344

Cite this

@article{6169f316a7cc451aba9ac2f9f2332310,

title = "Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.",

abstract = "AIMS: This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages. METHODS: The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of Clinical Pharmacy members, convened an independent committee to evaluate the role of compounded incretin mimetics. RESULTS: There is limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide. However, there remain significant legal and safety concerns since compounded incretins do not undergo approval by the Food and Drug Administration. CONCLUSION: Whenever possible, healthcare providers should make every effort to assist patients with obtaining approved medications. If patients choose to obtain compounded incretins, providers can encourage safety by ensuring use of reputable compounding pharmacies and routinely monitoring patients for safety and efficacy of the compounded product.",

author = "Courtney, \{Lindsay A\} and Clements, \{Jennifer N\} and Diana Isaacs and Pitlick, \{Jamie M\} and Reece, \{Sara Mandy\} and Whitley, \{Heather P\}",

year = "2025",

month = sep,

day = "1",

doi = "10.1016/j.dsx.2025.103314",

language = "American English",

volume = "19",

journal = "Diabetes and Metabolic Syndrome",

number = "9",

}

TY - JOUR

T1 - Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.

AU - Courtney, Lindsay A

AU - Clements, Jennifer N

AU - Isaacs, Diana

AU - Pitlick, Jamie M

AU - Reece, Sara Mandy

AU - Whitley, Heather P

PY - 2025/9/1

Y1 - 2025/9/1

N2 - AIMS: This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages. METHODS: The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of Clinical Pharmacy members, convened an independent committee to evaluate the role of compounded incretin mimetics. RESULTS: There is limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide. However, there remain significant legal and safety concerns since compounded incretins do not undergo approval by the Food and Drug Administration. CONCLUSION: Whenever possible, healthcare providers should make every effort to assist patients with obtaining approved medications. If patients choose to obtain compounded incretins, providers can encourage safety by ensuring use of reputable compounding pharmacies and routinely monitoring patients for safety and efficacy of the compounded product.

AB - AIMS: This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages. METHODS: The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of Clinical Pharmacy members, convened an independent committee to evaluate the role of compounded incretin mimetics. RESULTS: There is limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide. However, there remain significant legal and safety concerns since compounded incretins do not undergo approval by the Food and Drug Administration. CONCLUSION: Whenever possible, healthcare providers should make every effort to assist patients with obtaining approved medications. If patients choose to obtain compounded incretins, providers can encourage safety by ensuring use of reputable compounding pharmacies and routinely monitoring patients for safety and efficacy of the compounded product.

U2 - 10.1016/j.dsx.2025.103314

DO - 10.1016/j.dsx.2025.103314

M3 - Article

C2 - 41176849

VL - 19

JO - Diabetes and Metabolic Syndrome

JF - Diabetes and Metabolic Syndrome

IS - 9

ER -